- Home
- PMCB vs ORIS Comparison
PMCB vs ORIS Comparison
Compare PMCB & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- ORIS
- Stock Information
- Founded
- PMCB 1996
- ORIS 2014
- Country
- PMCB United States
- ORIS China
- Employees
- PMCB N/A
- ORIS N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- ORIS Farming/Seeds/Milling
- Sector
- PMCB Health Care
- ORIS Consumer Staples
- Exchange
- PMCB Nasdaq
- ORIS Nasdaq
- Market Cap
- PMCB 6.6M
- ORIS 5.3M
- IPO Year
- PMCB N/A
- ORIS 2024
- Fundamental
- Price
- PMCB $0.93
- ORIS $0.14
- Analyst Decision
- PMCB
- ORIS
- Analyst Count
- PMCB 0
- ORIS 0
- Target Price
- PMCB N/A
- ORIS N/A
- AVG Volume (30 Days)
- PMCB 106.5K
- ORIS 17.4M
- Earning Date
- PMCB 09-15-2025
- ORIS 01-01-0001
- Dividend Yield
- PMCB N/A
- ORIS N/A
- EPS Growth
- PMCB N/A
- ORIS N/A
- EPS
- PMCB 0.01
- ORIS 0.17
- Revenue
- PMCB N/A
- ORIS $15,014,000.00
- Revenue This Year
- PMCB N/A
- ORIS N/A
- Revenue Next Year
- PMCB N/A
- ORIS N/A
- P/E Ratio
- PMCB $160.47
- ORIS $0.83
- Revenue Growth
- PMCB N/A
- ORIS N/A
- 52 Week Low
- PMCB $0.80
- ORIS $0.08
- 52 Week High
- PMCB $2.42
- ORIS $56.01
- Technical
- Relative Strength Index (RSI)
- PMCB 44.27
- ORIS 46.56
- Support Level
- PMCB $1.00
- ORIS $0.11
- Resistance Level
- PMCB $1.08
- ORIS $0.20
- Average True Range (ATR)
- PMCB 0.08
- ORIS 0.02
- MACD
- PMCB -0.00
- ORIS 0.01
- Stochastic Oscillator
- PMCB 2.95
- ORIS 34.85
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).